Empfehlungen zur kalkulierten parenteralen Initialtherapie ...

Klaus-Friedrich Bodmann, Béatrice Grabein und die Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.
16. Driscoll JA, Brody SL, Kollef MH. The
epidemiology, pathogenesis and treatment
of Pseudomonas aeruginosa infections.
Drugs 2007;67:351-68.
17. Dupont H. The empiric treatment of
nosocomial intra-abdominal infections.
Int J Infect Dis 2007;11:1-6.
18. Eckmann C, Leitner E, Heizmann W,
Bodmann KF. Wirksamkeit von Tigecy clin
bei komplizierten Infektionen unter Routinebdingungen
in Deutschland. Posterpräsentation
DIVI 2008, Hamburg.
19. Edelsberg J, Berger A, Schell S, Mallick
R, et al. Economic consequences of
failure of initial antibiotic therapy in
hopitalized adults with complicated
intra-abdominal infections. Surg Infect
2008;9:335-47.
20. Eggimann P, Francioli P, Bille J, Schneider
R, et al. Fluconazole prophylaxis
prevents intra-abdominal candidiasis
in high-risk surgical patients. Crit Care
Med 1999;27:1066-72.
21. Engel C, Brunkhorst FM, Bone HG,
Brunkhorst R, et al. Epidemiology of
sepsis in Germany: results from a national
prospective multicenter study. Intensive
Care Med 2007;33:606-18.
22. Fleig WE, Grothe W, Lotterer E, Behl
S. Spontan bakterielle Peritonitis.
Retro spektive und prospektive Daten
einer multizentrischen Studie zu Prävalenz,
Diagnostik und Therapie in
Deutschland. Dtsch Med Wochenschr
2004;129:1792-7.
23. Giske CG, Monnet DL, Cars O, Carmeli
Y, et al. Clinical and economic impact
of common multidrug-resistant gramnegative
bacilli. Antimicrob Agents
Chemother 2008;52:813-21.
24. Halle E, Padberg J, Rosseau S, Klare I,
et al. Linezolid-resistant Enterococcus
faecium and Enterococcus faecalis isolated
from a septic patient: report of
first isolates in Germany. Infection
2004;32:182-3.
25. Harbarth S, Uckay I. Are there any patients
with peritonitis who require empiric
therapy for enterococcus? Eur J
Microbiol Infect Dis 2004;23:73-7.
26. Hau T, Ohmann C, Wolmershauser A,
Wacha H, et al. Planned relaparotomy
versus relaparotomy on demand in the
treatment of intraabdominal infections.
Arch Surg 1995;130:1193–7.
27. Isenmann R, Rünzi M, Kron M. Prophylactic
antibiotic treatment in patients
with predicted severe acute pancreatitis:
a placebo-controlled, double-blind trial.
Gastroenterology 2004;126:997-1004.
28. Jaccard C, Troillet N, Harbarth S, Zanetti
G, et al. Propsective randomized comparison
of imipenem-cilastatin and
piperacillin-tazobactam in nosocomial
pneumonia and peritonitis. Antimicrob
Agents Chemother 1998;42:2966-75.
29. Krepel CJ, Gohr CM, Edmiston CE, Condon
RE. Surgical sepsis: constancy of
antibiotic susceptibility of causative
organisms. Surgery 1995;117:505-8.
52
30. Kresken M, Hafner D, Schmitz FJ,
Wichelhaus TA, et al. Resistenz bei häufig
isolierten Enterobacteriaceae gegenüber
Breitspektrumantibiotika. Chemother
J 2006;15:179-90.
31. Kujath P (Hrsg.). Mykosen in der operativen
Medizin. Grundlagen der Diagnostik
und Therapie. 1. Auflage. New
York: Georg Thieme Verlag Stuttgart;
1998:21-4.
32. Kujath P, Rodloff AC (Hrsg.). Peritonitis.
2. Auflage. Heidelberg: Uni-Med Verlag;
2005:13-5.
33. Kumar A, Roberts D, Wood KE, Light B,
et al. Duration of hypotension before
initiation of effective antimicrobial therapy
is the critical determinant of survival
in human septic shock. Crit Care
Med 2006;34:1589-96.
34. Lehner S, Grabein B, Pfaller P, Kopp R.
Bedeutung ESBL-produzierender Keime
für die klinische Chirurgie. Chirurg
2009;80:527-32.
35. Lima RC, Barreira A, Cardoso FL, Lima
MH, et al. Ciprofloxacin and cefazolin as
a combination for empirical initial therapy
of peritoneal dialysis-related peritonitis:
five-year follow-up. Perit Dial Int
2007;27:56-60.
36. Livermore DM. Beta-lactamases in laboratory
and clinical resistance. Clin Microbiol
Rev 1995;8:557-84.
37. Lucasti C, Jasovich A, Umeh O, Jiang J,
et al. Efficacy and tolerability of iv doripe
nem versus meropenem in adults
with complicated intra- abdominal infection:
a phase III, prospective, multicenter,
randomized, double-blind noninferiority
study. Clin Ther 2008;30:
868-83.
38. Malangoni MA, Song J, Herrington J,
Choudhri S, et al. Randomized controlled
trial of moxifloxacin compared
with piperacillin-tazobactam and amoxicillin-calvulanate
for the treatment of
complicated intraabdominal infections.
Ann Surg 2006;244:204-11.
39. Masterton RG, Galloway A, French G,
Street M, et al. Guidelines for the management
of hospital-acquired pneumonia
in the UK. J Anticrob Chemother
2008;62:5-34.
40. Mazaki T, Ishii Y, Takayama T. Metaanalysis
of prophylactic use in acute
necrotizing pancreatitis. Br J Surg
2006;93:674-84.
41. Mazuski JE. Antimicrobial treatment for
intraabdominal infections. Expert Opin
Pharmacother 2007;8:2933-45.
42. Montravers P, Dupont H, Gauzit R,
Veber B, et al. Candida as a risk factor
for mortality in peritonitis. Crit Care
Med 2006;34:646-52.
43. Nathens AB, Cook CH, Machiedo G,
Moore EE, et al. Defining the research
agenda for surgical infection: a consensus
of experts using the Delphi
approach. Surg Infect (Larchmt) 2006:7:
101-9.
44. Nathens AB, Curtis JR, Beale RJ, Cook
DJ, et al. Management of the critically ill
patient with severe acute pancreatitis.
Crit Care Med 2004;32:2524-36.
45. Nathens AB, Rotstein OD, Marshall JC.
Tertiary peritonitis: clinical features of a
complex nosocomial infection. World J
Surg 1998;22:158-63.
46. Nickols RL, Muzik AC. Enterococcal
infections in surgical patiens: the mystery
continues. Clin Infect Dis 1992;
15:72-6.
47. Pappas PG, Kauffman CA, Andes D,
Benjamin DK Jr, et al. Clinical practise
guidelines for the management of candidiasis:
2009 update by the Infectious
Diseases Society of America. Clin Infect
Dis 2009;48:503-35.
48. Paul M, Benuri-Silbiger I, Soares-Weiser
K, Leibovici L. Beta lactam monotherapy
versus beta lactam-aminoglycoside combination
therapy for sepsis in immunocompetent
patients: systematic review
and meta-analysis of randomised trials.
BMJ 2004;328(7441):668-78.
49. Paul M, Silbiger I, Grozinsky S, Soares-
Weiser K, et al. Beta lactam antibiotic
monotherapy versus lactam-aminoglycoside
antibiotic combination therapy
for sepsis. Cochrane Database Syst Rev
2006:CD003344.
50. Pelz RK, Hendrix CW, Swoboda SM,
Diener-West M, et al. Double-blind
placebo-controlled trial of fluconazole
to prevent candidal infections in critically
ill surgical patients. Ann Surg
2001;233:542-8.
51. Pfaller MA, Diekema DJ. Epidemiology
of invasive candidiasis: a persistent public
health problem. Clin Microbiol Rev
2007;20:133-63.
52. Rimola A, Garcia-Tsao G, Navasa M,
Piddock LJ, et al. Diagnosis, treatment
and prophylaxis of spontaneous bacterial
peritonitis: a consensus document.
J Hepatol 2000;32:142-53.
53. Roehrborn A., Thomas L, Potreck O,
Ebener C, et al. The microbiology of
postoperative peritonitis. Clin Infect Dis
2001;33:1513-9.
54. Solomkin JS, Mazuski JE, Bradley JS,
Rodvold KA, et al. Diagnosis and
management of complicated intraabdominal
infections in adults and
children: guidelines by the Surgical
Infection Society and the Infectious
Diseases Society of America. Clin Infect
Dis 2010;50:133-64.
55. Sort P, Navasa M, Arroyo V, Aldeguer
X, et al. Effect of intravenous albumin
on renal impairment and mortality in
patients with cirrhosis and spontaneous
bacterial peritonitis. N Eng J Med
1999;341:403-9.
56. Sotto A, Lefrant JY, Fabbro-Peray P, Muller
L, et al. Evaluation of antimicrobial
therapy management of 120 consecutive
patients with secondary peritonitis.
J Antimicrob Chemother 2002;50:569-
72.